Population pharmacokinetic model of Vancomycin based on therapeutic drug monitoring data in critically ill septic patients

被引:15
|
作者
Kovacevic, Tijana [1 ,2 ]
Miljkovic, Branislava [3 ]
Kovacevic, Pedja [1 ,2 ]
Dragic, Sasa [1 ,2 ]
Momcicevic, Danica [1 ,2 ]
Avram, Sanja [1 ]
Jovanovic, Marija [3 ]
Vucicevic, Katarina [3 ]
机构
[1] Univ Clin Ctr Republ Srpska, Dvanaest Beba Bb, Banja Luka 78000, Bosnia & Herceg
[2] Univ Banja Luka, Fac Med, Save Mrkalja 14, Banja Luka 78000, Bosnia & Herceg
[3] Univ Belgrade, Fac Pharm, Dept Pharmacokinet & Clin Pharm, Vojvode Stepe 450, Belgrade 11221, Serbia
关键词
Creatinine clearance; NONMEM; Renal function; Antibiotics; TDM;
D O I
10.1016/j.jcrc.2019.10.012
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Purpose: The present study aimed to establish a population pharmacokinetic model of vancomycin, including adult critically ill septic patients, with normal and impaired renal function. Materials and methods: A prospective analysis of 146 concentrations from 73 adult critically ill septic patients treated with 1-h intravenous infusion of vancomycin were included in the study. A nonlinear mixed effects modeling (NONMEM) approach was applied for data analysis and evaluation of the final model. The influence of creatinine clearance calculated by the Cockcroft-Gault equation (CrCl), and other potential covariates on vancomycin clearance (CL) were evaluated. Results: The final one-compartment pharmacokineticmodel includes the effect of CrCl on CL. Population pharmacokinetic values for a typical subject were estimated at 0.024 l/h for CL dependent on renal function (CLCrCl), 1.93 l/h for residual portion of CL (not dependent on renal function), and 0.511 l/kg for volume of distribution (V). According to the final model, for patients with CrCl = 120 ml/min, the median vancomycin total CL is 4.81 l/h, while CrCl-dependent fraction accounts for approximately 60% of CL. Conclusions: The developed population vancomycin modelmay be used in estimating individual CL for adult critically ill septic patients, and could be applied for individualizing dosage regimens taking into account the continuous effect of CrCl. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页码:116 / 121
页数:6
相关论文
共 50 条
  • [21] Individualized Pharmacokinetic Dosing of Vancomycin Reduces Time to Therapeutic Trough Concentrations in Critically Ill Patients
    Truong, James
    Smith, Shawn R.
    Veillette, John J.
    Forland, Steven C.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (09): : 1123 - 1130
  • [22] A PHARMACOKINETIC EVALUATION OF VANCOMYCIN AND CEFEPIME IN CRITICALLY ILL NEUROSURGICAL PATIENTS
    Anliker, Lynn
    Foster, Charles
    Kiser, Tyree
    Mueller, Scott
    Sherman, Deb
    MacLaren, Robert
    Neumann, Robert
    Fish, Douglas
    CRITICAL CARE MEDICINE, 2012, 40 (12) : U255 - U255
  • [23] Pharmacokinetic Assessment of Vancomycin Loading Dose in Critically Ill Patients
    Alvarez, Osvaldo
    Cristian Plaza-Plaza, Jose
    Ramirez, Manuel
    Peralta, Alexis
    Amador, Cristian A.
    Amador, Roberto
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (08)
  • [24] Implementing Vancomycin Population Pharmacokinetic Models: An App for Individualized Antibiotic Therapy in Critically Ill Patients
    Mena, Manuel
    Garcia, Julio-Cesar
    Bustos, Rosa-Helena
    ANTIBIOTICS-BASEL, 2023, 12 (02):
  • [25] External validation of pharmacokinetic population model of thiopental in critically ill patients
    Marsot, A.
    Goirand, F.
    Milesi, N.
    Dumas, M.
    Boulamery, A.
    Simon, N.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2011, 25 : 90 - 90
  • [26] An HPLC assay for the therapeutic drug monitoring of cefiderocol in critically ill patients
    Mernissi, Touria
    Bodeau, Sandra
    Andre, Camille
    Zahr, Noel
    Mary, Aurelien
    Dupont, Herve
    Kontar, Loay
    Lemaire-Hurtel, Anne-Sophie
    Bennis, Youssef
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2021, 76 (06) : 1643 - 1646
  • [27] Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data
    Vucicevic, Katarina
    Milijkovic, Branislava
    Velickovic, Ruzica
    Pokrajac, Milena
    Mrhar, Ales
    Grabnar, Iztok
    THERAPEUTIC DRUG MONITORING, 2007, 29 (06) : 781 - 788
  • [28] Therapeutic drug monitoring of β-lactams for critically ill patients: unwarranted or essential?
    Roberts, Jason A.
    Hope, William W.
    Lipman, Jeffrey
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2010, 35 (05) : 419 - 420
  • [29] THERAPEUTIC DRUG MONITORING IS MANDATORY IN CRITICALLY ILL PATIENTS TREATED WITH VORICONAZOLE
    Algera, M.
    van Wanrooy, M. J. P.
    Rodgers, M. G. G.
    Uges, D. R. A.
    Kosterink, J. G. W.
    van der Werf, T. S.
    Alffenaar, J. W. C.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 72 (05) : 843 - 843
  • [30] Therapeutic Drug Monitoring of Gentamicin Peak Concentrations in Critically Ill Patients
    Hodiamont, Caspar J.
    Janssen, Julie M.
    de Jong, Menno D.
    Mathot, Ron A.
    Juffermans, Nicole P.
    van Hest, Reinier M.
    THERAPEUTIC DRUG MONITORING, 2017, 39 (05) : 522 - 530